Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:PRTC NASDAQ:RXRX NASDAQ:SLS NYSE:TRLV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePRTCPureTech Health$17.42$17.44$14.50▼$19.92$424.04M1.1518,480 shsN/ARXRXRecursion Pharmaceuticals$3.67-0.5%$3.30$2.77▼$7.18$1.96B1.0419.94 million shs23.11 million shsSLSSELLAS Life Sciences Group$14.76-4.5%$7.54$1.39▼$15.88$3.04B2.59.08 million shs21.50 million shsTRLVTrulieve Cannabis$9.86+6.7%$0.00$3.54▼$13.28$1.90BN/A595,824 shs1.50 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePRTCPureTech Health0.00%0.00%0.00%+14.07%+0.99%RXRXRecursion Pharmaceuticals-0.54%+15.77%+2.23%+19.93%-27.47%SLSSELLAS Life Sciences Group-4.47%+62.73%+58.54%+250.59%+573.97%TRLVTrulieve Cannabis+6.29%+14.75%+985,699,900.00%+985,699,900.00%+985,699,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePRTCPureTech Health$17.42$17.44$14.50▼$19.92$424.04M1.1518,480 shsN/ARXRXRecursion Pharmaceuticals$3.67-0.5%$3.30$2.77▼$7.18$1.96B1.0419.94 million shs23.11 million shsSLSSELLAS Life Sciences Group$14.76-4.5%$7.54$1.39▼$15.88$3.04B2.59.08 million shs21.50 million shsTRLVTrulieve Cannabis$9.86+6.7%$0.00$3.54▼$13.28$1.90BN/A595,824 shs1.50 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePRTCPureTech Health0.00%0.00%0.00%+14.07%+0.99%RXRXRecursion Pharmaceuticals-0.54%+15.77%+2.23%+19.93%-27.47%SLSSELLAS Life Sciences Group-4.47%+62.73%+58.54%+250.59%+573.97%TRLVTrulieve Cannabis+6.29%+14.75%+985,699,900.00%+985,699,900.00%+985,699,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePRTCPureTech Health 1.00SellN/AN/ARXRXRecursion Pharmaceuticals 2.20Hold$8.10120.71% UpsideSLSSELLAS Life Sciences Group 2.00Hold$10.00-32.25% DownsideTRLVTrulieve Cannabis 1.50ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest PRTC, RXRX, SLS, and TRLV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2026TRLVTrulieve Cannabis Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold6/16/2026TRLVTrulieve Cannabis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell (D-)5/18/2026PRTCPureTech Health Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/14/2026RXRXRecursion Pharmaceuticals Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$5.00 ➝ $5.505/7/2026RXRXRecursion Pharmaceuticals Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.004/30/2026RXRXRecursion Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$11.00 ➝ $10.004/21/2026PRTCPureTech Health Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)4/21/2026RXRXRecursion Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026SLSSELLAS Life Sciences Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPRTCPureTech Health$4.66M91.01N/AN/A$12.65 per share1.38RXRXRecursion Pharmaceuticals$74.68M26.04N/AN/A$2.14 per share1.71SLSSELLAS Life Sciences GroupN/AN/AN/AN/A$0.46 per shareN/ATRLVTrulieve Cannabis$1.17B1.62N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePRTCPureTech Health-$109.74MN/AN/AN/AN/AN/AN/AN/A8/27/2026 (Estimated)RXRXRecursion Pharmaceuticals-$644.76M-$1.20N/AN/AN/A-842.95%-54.33%-40.60%8/4/2026 (Estimated)SLSSELLAS Life Sciences Group-$26.86M-$0.23N/AN/AN/AN/A-47.12%-42.63%8/11/2026 (Estimated)TRLVTrulieve CannabisN/AN/AN/AN/AN/AN/AN/AN/AN/ALatest PRTC, RXRX, SLS, and TRLV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026SLSSELLAS Life Sciences Group-$0.06-$0.05+$0.01-$0.05N/AN/A5/6/2026Q1 2026RXRXRecursion Pharmaceuticals-$0.30-$0.22+$0.08-$0.22$15.78 million$6.47 million4/10/2026H2 2025PRTCPureTech HealthN/A-$1.35N/A-$1.35N/A$1.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthPRTCPureTech HealthN/AN/AN/AN/AN/ARXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ATRLVTrulieve CannabisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPRTCPureTech HealthN/A6.596.59RXRXRecursion Pharmaceuticals0.015.475.47SLSSELLAS Life Sciences GroupN/A17.2217.22TRLVTrulieve CannabisN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPRTCPureTech Health0.04%RXRXRecursion Pharmaceuticals89.06%SLSSELLAS Life Sciences Group17.38%TRLVTrulieve CannabisN/AInsider OwnershipCompanyInsider OwnershipPRTCPureTech Health5.30%RXRXRecursion Pharmaceuticals6.65%SLSSELLAS Life Sciences Group1.30%TRLVTrulieve CannabisN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionablePRTCPureTech Health10024.34 million23.05 millionNot OptionableRXRXRecursion Pharmaceuticals400529.91 million494.67 millionOptionableSLSSELLAS Life Sciences Group10196.63 million194.08 millionNot OptionableTRLVTrulieve Cannabis9,000192.31 millionN/AN/APRTC, RXRX, SLS, and TRLV HeadlinesRecent News About These CompaniesKim Rivers Sells 136,811 Shares of Trulieve Cannabis (NYSE:TRLV) StockJune 28 at 5:43 AM | americanbankingnews.comTrulieve CEO Sells $1.2 Million in Stock as Shares Jump 148% in One YearJune 27, 2026 | fool.comTrulieve Cannabis (NYSE:TRLV) CEO Sells 136,811 SharesJune 27, 2026 | insidertrades.comKim Rivers Sells 380,000 Shares of Trulieve Cannabis (NYSE:TRLV) StockJune 27, 2026 | americanbankingnews.comKim Rivers Sells 300,000 Shares of Trulieve Cannabis (NYSE:TRLV) StockJune 27, 2026 | americanbankingnews.comKim Rivers Sells 400,000 Shares of Trulieve Cannabis (NYSE:TRLV) StockJune 27, 2026 | americanbankingnews.comPromising Cannabis Stocks To Follow Today - June 26thJune 27, 2026 | americanbankingnews.comTrulieve Announces Planned Termination of Executive Automatic Securities Disposition PlanJune 26, 2026 | prnewswire.comTRLV PE / PEG RatioJune 26, 2026 | seekingalpha.comInsider Selling: Trulieve Cannabis (NYSE:TRLV) CEO Sells $2,451,000.00 in StockJune 26, 2026 | insidertrades.comBest Cannabis Stocks Worth Watching - June 25thJune 26, 2026 | americanbankingnews.comTop Cannabis Stocks To Follow Now - June 24thJune 25, 2026 | americanbankingnews.comTRLV Trulieve Cannabis Corp.June 24, 2026 | seekingalpha.comCannabis Stocks To Follow Now - June 23rdJune 24, 2026 | americanbankingnews.comCannabis Stocks To Watch Today - June 22ndJune 23, 2026 | americanbankingnews.comTrulieve Cannabis (NYSE:TRLV) CEO Kim Rivers Sells 139,846 Shares of StockJune 23, 2026 | americanbankingnews.comTrulieve Cannabis (NYSE:TRLV) CEO Kim Rivers Sells 204,815 Shares of StockJune 23, 2026 | americanbankingnews.comTrulieve Cannabis (NYSE:TRLV) CEO Kim Rivers Sells 137,535 SharesJune 23, 2026 | americanbankingnews.comTrulieve Cannabis (NYSE:TRLV) CEO Sells $1,287,327.60 in StockJune 23, 2026 | insidertrades.comCannabis Stocks To Follow Today - June 19thJune 20, 2026 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRTC, RXRX, SLS, and TRLV Company DescriptionsPureTech Health NASDAQ:PRTC$17.42 0.00 (0.00%) As of 06/29/2026PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Recursion Pharmaceuticals NASDAQ:RXRX$3.67 -0.02 (-0.54%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$3.66 -0.01 (-0.27%) As of 04:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.SELLAS Life Sciences Group NASDAQ:SLS$14.76 -0.69 (-4.47%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$14.56 -0.20 (-1.33%) As of 04:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.Trulieve Cannabis NYSE:TRLV$9.86 +0.62 (+6.68%) Closing price 06/30/2026 03:59 PM EasternExtended Trading$9.50 -0.36 (-3.61%) As of 04:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, California, Massachusetts, Connecticut, Pennsylvania, and West Virginia, as well as directly to patients through home delivery. It produces approximately 550 stock keeping units, including flower, edibles, vaporizer cartridges, concentrates, topicals, capsules, tinctures, dissolvable powders, and nasal sprays. As of May 5, 2021, the company operated through 87 dispensaries in the United States. The company is headquartered in Quincy, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Dividend Stocks Could Boost Your Income This July The Quantum Bubble Is Real Enough to Take Seriously Amazon Could Be About to Reap the Rewards of a Software Spending Boom Even CEOs Need Cash: Insider Selling Is Not the Only Signal in AI Stocks Why Wall Street Still Sees Massive Upside for AeroVironment Stock AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed? Manchester United’s Stock Rally Faces a Test Beyond Old Trafford NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
